Background: The Biochemistry and Haematology Outcome Model (BHOM) relies on the results from routine index blood tests to predict the patient risk of death. We aimed to externally validate the BHOM model. Method: We considered all emergency adult medical patients who were discharged from Northern Lincolnshire and Goole (NLAG) hospital in 2014. We compared patient characteristics between NLAG (the validation sample) and the hospital where BHOM was developed. We evaluated the predictive performance, according to discriminative ability (with a concordance statistic, c), and calibration (agreement between observed and predicted risk). Result: There were 29 834 emergency discharges of which 24 696 (83%) had complete data. In comparison with the development sample, the NLAG sample was similar in age, blood test results, but experienced a lower mortality (4.7 vs. 8.7%). When applied to NLAG, the BHOM model had good discrimination (c-statistic 0.83 [95% CI 0.823-0.842]). Calibration was good overall, although the BHOM model overpredicted for lowest (<5%, observed ¼ 229, predicted ¼ 286) and highest (!50%, observed ¼ 31, predicted ¼ 49) risk groups, even after recalibrating for the differences in baseline risk of death. Conclusion: Differences in patient case-mix profile and baseline risk of death need to be considered before the BHOM model can be used in another hospital. After re-calibrating for the baseline difference in risk the BHOM model had good discrimination but less adequate calibration.
Introduction
Statistically derived risk equations are widely used to support healthcare professionals in the research, audit and delivery of healthcare. Examples of risk equations include Acute Physiology and Chronic Health Evaluation, 1 
Mortality
Probability Model 2 and for more examples see. 3 Typically the risk equations are developed by randomly splitting the data into two parts-'training' and 'testing'. This approach, known as internal validation, 4 has been criticised because (i) the subsequent model performance statistics are optimistic and (ii) typically, the use of the risk equation is beyond the settings where the equation was first developed and internal validation does not give any indication about the performance of the model in another setting. The use of external validation, where the model is tested using data from another setting, is now seen as an important step in model development. [4] [5] [6] [7] [8] The Biochemistry and Haematology Outcome Model (BHOM) was developed by researchers at Portsmouth Hospital NHS Trust based on routinely collected biochemistry and haematology blood test results along with basic demographic information for 9497 adults discharged from a medical speciality hospital during one year (January 2001-December 2001). A major advantage of the BHOM model is that the covariates are clinically meaningful, collected as part of the process of care and these data are available within a few hours of the patient admission. The BHOM model was internally validated and found to have good discrimination (c-statistics 0.757-0.779) and good calibration (non-significant p-values from the HosemerLemeshow deciles of risk table). 9, 10 Nonetheless the BHOM model has not been externally validated-an important step before it can used outside of the hospital in which it was developed. We aimed to externally validate the BHOM model, by considering its calibration and discrimination in a cohort of patients discharged from another hospital following an acute admission.
Methods

Setting and data for external validation
Our cohort of emergency admissions is from the Northern Lincolnshire and Goole NHS Foundation Trust (NLAG) in England. All 24 696 adults (age ! 16 years) emergency patients discharged during the year 2014 (1 January 2014-31 December 2014) were included. For each admission we obtained the patients age, gender (male/female), discharge status (alive/dead) and index blood test results used in the BHOM model from the hospital computer system. The covariates set was: 'age' on admission (years), 'gender' (female ¼ 0/male ¼ 1), 'albumin' (g/;), 'creatinine' (mmol/l), 'haemoglobin', 'potassium' (mmol/l), 'sodium' (mmol/l), 'white cell count' (10 9 cells/l), 'urea' (mmol/l), and ratio of 'urea' (mmol/l) and 'creatinine' (mmol/l). We also considered records which had no missing data (24 696/29 834 (83%)), as did here. 9 We did not consider elective patients because the intended use of the BHOM model in NLAG was for acute medical patients.
The BHOM model
The BHOM risk equation is shown below:
Where R is risk of death in hospital and the variables gender and mode of admission are coded female ¼ 0, male ¼ 1, elective ¼ 0, and emergency ¼ 1, respectively. The other covariates are continuous values based on routine blood test results.
Statistical analyses
We followed a previously proposed framework for the external validation of clinical prediction models. 6 There are two key steps:
i. To determine the relatedness of the patients in the model development sample with the patients in the external validation sample. This preliminary step helps to determine the extent to which the model is being validated in a patient population that is not materially dissimilar to the development sample. ii. To assess the performance of the model on the external validation sample by determining the model discrimination and calibration. For discrimination, we use the area under the receiver-operator curve (AUROC) or concordance (c)-statistic. AUROC is the probability that the model will predict a higher risk of death for a randomly selected patient who died, compared with a randomly selected patient who survived. 4, 5 Calibration is the relationship between the observed and predicted risk of death and can be usefully seen on a scatter plot (y-axis observed risk, x-axis predicted risk). Perfect predictions should be on the 45 line. The intercept (a) and slope (b) of this line gives an assessement of 'calibration-in-the-large'. 11 At model development, a ¼ 0 and b ¼ 1, but at validation, calibration-in-the-large problems are indicated if a is not 0 and if b is more/less than 1 as this reflects problems of under/over prediction. 5 We also use the Table 2 ).
Before we could apply the BHOM model we made two adjustments based on preliminary observations. (i) We divided the NLAG 'haemoglobin' results by 10 to ensure they were compatible with units for 'haemoglobin' in the BHOM model. (ii) We noted that the mortality in NLAG is almost half that of Portsmouth Hospital (4.69 vs. 8.7%). To correct for this difference in baseline risk we adjusted the constant term in the BHOM model, by trial and error (see supporting Microsoft Excel file) and selecting the value (À11.3235) which produced optimal calibration. The mean risk of death for NLAG from the model with the revised constant was thus similar with BHOM model 4.69%. 12 
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Results
Cohort description
There were 29 834 emergency discharges from during the year 2014, of which 24 696 (83%) had complete data. The mean age of patients was 63.1 years (SD 21.1), the female to male ratio was 1.14 and the in-hospital mortality was 4.69% (1159/24 696). The relationship between the continuous covariates and mortality are shown in Figures 1 and 2 .
External validation results
Step 1: relatedness of the patient samples The mean and SD for each continuous covariates showed no major differences between the development sample (Portsmouth Hospital) and external validation sample (NLAG), with the exception of albumin which appear to be higher in Portsmouth. (see Table 1) Step 2: assessing the model performance We applied the BHOM model to the validation sample at NLAG. The resulting c-statistic (discrimination) was 0.833 (95% confidence interval 0.823-0.843) and the calibration in-the-large was a ¼ 0 and b ¼ 0:99. Calibration plots (Fig. 3 ), without and with re-calibration for differences in baseline risk showed systematic over prediction which still persisted in the higher risk (risk > 0.40) groups.
The H-L deciles of risk calibration test (see Table 2 ), after recalibrating for baseline differences, was statistically significant P < 0. 001 where there were 119 observed deaths compared with 95 predicted deaths.
Discussion
The performance of the BHOM model based on internal validation was good -the discrimination (c-statistic) for BHOM was 0.757-0.779 and the HL deciles of risk calibration produced no statistically significant difference between predicted and observed mortality (P > 0.05). We undertook an external validation exercise for the BHOM model using data for emergency medical admissions at NLAG hospital over one year. As far as we are aware, this is the first external validation attempt of the BHOM model. We found that after re-calibrating for the baseline difference in risk between the two cohorts of patients, the BHOM model had good discrimination, but less adequate calibration -it over predicted for lowest (<5%, observed ¼ 229, predicted ¼286) and highest (!50%, observed ¼ 31, predicted ¼ 49) risk groups. Although the BHOM model has attractive features of using results from routine blood tests (without additional data collection) its use outside of hospital in which it was developed requires attention to two key issues. (i) Consideration and, where necessary, correction for differences in baseline risk by adjusting the constant term in the BHOM model. (ii) Investigation of predicted vs. observed risk as seen in a calibration plots, which in our case, showed that differences persisted even after correcting for baseline differences in risk of death. The inadequate calibration is not readily explained by difference in the distribution of continuous and categorical covariates. Further work to consider reasons for inadequate calibration are required. There are several possible issues. (i) The sample sizes at NLAG are almost three times as large as Portsmouth hospital (24 696 vs. 9497). This would increase the risk of spuriously low P-values which are statistically significant but clinically insignificant (ii) The calibration deteriorates in higher (!50%) risk groups and so the model predictions could be capped at this threshold. (iii) The relationship between covariates and risk of death may be significantly different in NLAG vs. a Portsmouth hospital. This could be explored using tests for interactions. Nonetheless it is worth emphasizing that whilst these desktop approaches are useful and can correct for some issues in model performance, the ultimate question is to determine the extent to which such risk equations support clinical decision making and enhance safety and quality of patient care.
Conclusion
Differences in patient case-mix profile and baseline risk of death need to be considered before the BHOM model can be used in another hospital. We found that after re-calibrating for the baseline difference in risk between the two cohorts of patients, the BHOM model had good discrimination, but less adequate calibration.
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